Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion type Assertion NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_head.
- NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion description "[By liquid culture of leukemia cell lines and fresh AML cells with the addition of all-trans retinoic acid (ATRA), modulation of P-gp/MDR1 and Egr1 was observed and the pattern of modulation was divided into four groups: (1) blastic AML type, in which distinct expression of P-gp/MDR1 and CD34 was not influenced by ATRA; (2) t(8;21)AML type, in which P-gp/MDR1 expression was augmented by ATRA, while CD34 was kept high; (3) AML M3 type, in which P-gp/MDR1 expression was reduced with granulocytic differentiation by ATRA; (4) monocytic AML type, in which P-gp/MDR1 expression was augmented by ATRA, while CD34 expression decreased, and strong Egr1 expression was downregulated just prior to the augmentation of P-gp/MDR1 expression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_provenance.
- NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion evidence source_evidence_literature NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_provenance.
- NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion SIO_000772 11734301 NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_provenance.
- NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion wasDerivedFrom befree-20150227 NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_provenance.
- NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_assertion wasGeneratedBy ECO_0000203 NP370883.RAXpsg0TcxxXg8WGYU24EYpSqwVDg_saoSDCjn1n7oFRo130_provenance.